Literature DB >> 23546518

Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML.

Vanessa Marchesi.   

Abstract

Entities:  

Year:  2013        PMID： 23546518     DOI： 10.1038/nrclinonc.2013.51

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Andreas Hochhaus; Giuseppe Saglio; Richard A Larson; Dong-Wook Kim; Gabriel Etienne; Gianantonio Rosti; Carmino De Souza; Mineo Kurokawa; Matt E Kalaycio; Albert Hoenekopp; Xiaolin Fan; Yaping Shou; Hagop M Kantarjian; Timothy P Hughes
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113
  1 in total
  1 in total

1.  Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Zafar Iqbal; Muhammad Absar; Amer Mahmood; Aamer Aleem; Mudassar Iqbal; Abid Jameel; Tanveer Akhtar; Sajjad Karim; Mahmood Rasool; Zeenat Mirza; Muhammad Khalid; Afia Muhammad Akram; Muhammad Farooq Sabar; Ahmad M Khalid; Khalid Aljarrah; Janhangir Iqbal; Muhammad Khalid; Ijaz H Shah; Nawaf Alanazi
Journal:  Asian Pac J Cancer Prev       Date:  2020-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.